Randomised double blind crossover study comparing ondansetron, granisetron and tropisetron. A cost-benefit analysis

Supportive Care in Cancer

Volumn 8, Issue 4, 2000, Pages 323-333

  Barrajon, Enrique ^a   De Las Peñas, Ramon ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^b HOSPITAL GENERAL DE CASTELLÓN   (Spain)

Author keywords

Antiemetics; Cost benefit analysis; Emesis; Randomised controlled clinical trial

Indexed keywords

GRANISETRON; METOCLOPRAMIDE; ONDANSETRON; TROPISETRON;

ARTICLE; CANCER GRADING; CLINICAL TRIAL; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTONINERGIC NERVE CELL; TREATMENT PLANNING; VOMITING;

EID: 0033921734     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005209900120     Document Type: Article

References (107)

1. 3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis. Drugs 42:551-562
2. Aapro MS (1991) Controlling emesis related to cancer therapy. Eur J Cancer 27:356-361
3. Aapro MS (1993) Review of experience with ondansetron and granisetron. Ann Oncol 4 [Suppl 3]:S9-14
4. Ahn MJ, Lee JS, Lee KH, Suh C, Choi SS, Kim SH (1994) A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy. Am J Clin Oncol 17:150-156
5. 3 receptor antagonists the same? Eur J Cancer [A] 28 [Suppl]:S2-6
6. Armitage P, Berry G (1992) Estadística para la investigation biomédica. Doyma, Barcelona
7. Ballatori E, Roila F, Berto P, et al (1994) Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy. Pharmacoeconomics 5:227-237
8. Beck TM, Hesketh PJ, Madajewicz S, et al (1992) Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 10:1969-1975
9. Beck TM, Ciociola AA, Jones SE, et al (1993) Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 118:407-413
10. Beck TM, York M, Chang A, et al (1997) for the S3A-376 Study Group. Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Cancer Invest 15:297-303
11. Berger A, Clark-Snow RA (1997) Nausea and vomiting. In: De Vita VT, Hellman S, Rosenberg S (eds) Cancer principles and practice of oncology. Lippincott, Philadelphia, pp 2705-2714
12. Bleiberg HH, Spielmann M, Falkson G, Romain D (1995) Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study. Clin Ther 17:38-51
13. Bonneterre J, Hecquet B (1995) Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy. A cross-over study. Bull Cancer 82:1038-1043
14. Brown GW, Paes D, Bryson J, et al (1992) The effectiveness of a single intravenous dose of ondansetron. Oncology 49:273-278
15. Buxton MJ, O'Brien BJ (1992) Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting. Br J Cancer 66 [Suppl 19]:64-67
16. Campora E, Simoni C, Rosso R (1994) Tropisetron verso ondansetron nella prevenzione e controllo dell'emesi in pazienti sottoposte a chemioterapia con FAC/FEC per carcinoma mammario metastatico o operato. Minerva Med 85:25-31
17. Chevallier B, on behalf of the Granisetron Study Group (1990) Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. Eur J Cancer 26 [Suppl 1]:S33-36
18. Coates A, Abraham S, Kaye SB, et al (1983) On the receiving end - patient perception of the side effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203-208
19. Cubeddu LX, Pendergrass K. Ryan T, et al (1994) Efficacy or oral ondansetron, a selective antagonists of 5-HT3 receptors in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Am J Clin Oncol 17:137-146
20. Cunningham D, Gore M, Davidson N. et al (1993) The real cost of emesis: an economic analysis of ondansetron vs metoclopramide in controlling emesis in patients receiving chemotherapy for cancer. Eur J Cancer [A] 29:303-306
21. Cunningham D, Dicato M, Verweij J, et al (1996) Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam. Ann Oncol 7:277-282
22. Del Favero A, Tonato M, Roila F (1992) Issues in the measurement of nausea. Br J Cancer 66 [Suppl 19]:S69-71
23. Dilly S (1992) Are granisetron and ondansetron equivalent in the clinic: Eur J Cancer 28 [Suppl 1]:32S-35S
24. Eisenberg PD (1994) Further profiles of granisetron (Kytril): effect on quality of life and pharmacoeconomics. Semin Oncol 21 [Suppl 5]:26-29
25. Ettinger DS, Eisenberg PD, Fitts D, Wilson-Lynch K, Yocom K (1996) A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. Cancer 78:144-151
26. European Council (1998) Council regulation (EC) no. 2866/98 of 31 December 1998 on the conversion rates between the euro and the currencies of the Member States adopting the euro. Official Journal of the European Communities (L 359) 41:31 December 1998
27. Fox SM, Einhorn LH, Cox E, Powell N, Abdy A (1993) Ondansetron vs ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. J Clin Oncol 11:2391-2395
28. Fozard JR, Mobarok Ali AT (1978) Blockade of neuronal tryptamine receptors by metoclopramide. Eur J Pharmacol 49:109-112
29. Franklin HR, Simonetti GPC, Dubbelman AAC, et al (1994) Toxicity grading systems. A comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting. Ann Oncol 5:113-117
30. Gandara DR, Harvey WH, Monaghan GG, et al (1993) Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo. Eur J Cancer [A] 29 [Suppl 1]:S35-38
31. Gebbia V, Cannata G, Testa A, et al (1994) Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer 74:1945-1952
32. Goddard M (1993) The real costs of emesis. Eur J Cancer [A] 29:297-298
33. Gralla RJ (1989) An outline of antiemetic treatment. Eur J Cancer Clin Oncol 25 [Suppl 1]:S7-11
34. Granisetron Study Group (1993) The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. J Cancer Res Clin Oncol 119:555-559
35. Grunberg SM, Lane M, Lester EP, et al (1993) Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis. Cancer Chemother Pharmacol 32:268-272
36. Hedayati S, Moatti JP, Seitz JF (1994) Impact on ondansetron and granisetron on chemotherapy-induced emesis in adults: the need for comparative pharmacoeconomic data. Clin Ther 16:569-580
37. Heron JF, Goedhals L, Jordaan JP, et al (1994) Oral granisetron alone and in combination with dexamethasone: A double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. Ann Oncol 5:579-584
38. 3 receptor antagonists. Support Care Cancer 2:286-292
39. Hesketh PJ, Gandara DR (1991) Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 83:613-620
40. Hesketh PJ, Harvey WH, Harker WG, Beck TM, Ryan T, Bricker LJ, et al (1994) A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 12:596-600
41. Hesketh PJ, Beck T, Unlenhopp M, et al (1995) Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen. J Clin Oncol 13:2117-2122
42. Hesketh PJ, Kris MG, Grunberg SM, et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103-109
43. Huc P, Block S, Carlier D, et al (1998) Granisetron (per os) compare a ondansetron (per os) dans la prevention des nausées et vomissements induits par des chimiothérapies moyennement émétisantes. Bull Cancer 6:562-568
44. Italian Group for Antiemetic Research (1992) Ondansetron + dexamethasone versus metoclopramide + dexamethasone + diphenhydramine in the prevention of cisplatin-induced emesis. Lancet 340:96-99
45. Italian Group for Antiemetic Research (1995) Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332:1-5
46. Italian Group for Antiemetic Research (1995) Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 6:805-810
47. Italian Group for Antiemetic Research (1995) Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. J Clin Oncol 13:2417-2426
48. Italian Group for Antiemetic Research (1997) Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. J Clin Oncol 15:124-130
49. Jantunen IT, Kataja VV, Johansson RT (1992) Ondansetron and tropisetron with dexamethasone in the prophylaxis of acute vomiting induced by non-cisplatin-containing chemotherapy. Acta Oncol 31:573-575
50. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - a randomised study. Eur J Cancer [A] 29:1669-1672
51. Johnson N, Bosanquet N (1995) Cost effectiveness of 5-hydroxytryptamine3 receptor antagonists: a retrospective comparison of ondansetron and granisetron. Anticancer Drugs 6:243-249
52. 3 receptor antagonists in the management of chemotherapy-induced emesis. Eur J Cancer [A] 29:51-56
53. Kaiser L, Warr D, Hoskins P, Latreille J, et al (1994) Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:1050-1057
54. Kirchner V (1993) Clinical studies to assess the economic impact of new therapies: pragmatic approaches to measuring costs. Anticancer Drugs 4 [Suppl 3]:13-20
55. Kris MG, Gralla RJ, Tyson LB, et al (1989) Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 7:108-114
56. Laszlo J (1981) Emesis as a critical point in chemotherapy. N Engl J Med 305:948-949
57. Latreille J, Pater J, Johnston D, et al (1998) Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J Clin Oncol 16:1174-1178
58. Leonardi V, Iannito E, Meli M, et al (1996) Ondansetron (OND) vs granisetron (GRA) in the control of chemotherapy induced acute emesis: a multicentric randomized trial. Oncol Rep 3:919-923
59. Mantovanni G, Maccio A, Bianchi A, et al (1996) Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer 77:941-948
60. Martoni A, Angelelli B. Guaraldi M, et al (1996) An open randomized cross-over study of granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens. Eur J Cancer [A] 32:82-85
61. Marty M (1990) A comparative study of the use of granisetron, a selective 5HT antagonist versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. Eur J Cancer 26 [Suppl 1]:S28-32
62. Marty M, Keilsbauer JP, Fournel P, et al (1995) Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis)? The French Navoban Study Group. Anticancer Drugs 6 [Suppl 1]:15-21
63. Marty M, Pouillart P, Scholl S, et al (1990) Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322:816-821
64. 3-receptor-antagonist in moderately emetogenic chemotherapy. J Chemother 8:237-242
65. Miner WD, Sanger GJ (1986) Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 88:497-499
66. Morrow GR, Hickok JT, Rosenthal SN (1995) Progress in reducing nausea and emesis. Cancer 76:343-357
67. Multinational Association of Supportive Care in Cancer (MASCC): Antiemetic Subcommittee (1998) Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Ann Oncol 9:811-819
68. Navari R, Gandara D, Hesketh P, et al (1995) Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 13:1242-1248
69. Nicolai N, Mangiarotti B, Salvioni R. Piva L, Faustini M, Pizzocaro G (1993) Dexamethasone plus ondansetron versus dexamethasone plus alizapride in the prevention of emesis induced by cisplatin-containing chemotherapies for urological cancers. Eur Urol 23:450-456
70. Noble A, Bremer K, Goedhals L, et al (1994) A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur J Cancer [A] 30:1083-1088
71. Olver I, Paska W, Depierre A, Seitz J-F, Stewart DJ, Goedhals L, et al (1996) A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ann Oncol 7:945-952
72. Olver IN (1992) Antiemetic study design: desirable objectives, stratifications and analyses. Br J Cancer 66 [Suppl 19]:S30-34
73. Park JO, Rha SY, Yoo NC, et al (1997) A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy. Am J Clin Oncol 29:569-572
74. 3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol 8:181-185
75. Perez EA (1995) Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 13:1036-1043
76. 3 receptor antagonists in antineoplastic therapy-induced emesis. Drug Safety 18:53-56
77. Perez EA, Hesketh P, Sandbach J, et al (1998) Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. A multicenter, double-blind, randomized parallel study. J Clin Oncol 16:754-760
78. Perez EA, Navari RM. Kaplan HG, et al (1997) Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis. Support Care Cancer 5:31-37
79. Plosker GL, Benfield P (1996) Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting. Pharmacoeconomics 9:357-374
80. Rath U, Upadhyaya BK, Arechavala E, et al (1993) Role of ondansetron plus dexamethasone in fractionated chemotherapy. Oncology 50:168-172
81. Roila F, Ballatori E (1998) The efficacy and cost-effectiveness of various antiemetic regimens. Curr Opin Oncol 10:310-315
82. Roila F, Del Favero A (1997) Antiemetics revisited. Curr Opin Oncol 9:321-326
83. Roila F, Tonato M, Cognetti F, et al (1991) Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9:675-678
84. Roila F, Tonato M, Basurto C, et al (1993) Ondansetron. Eur J Cancer [A] 29 [Suppl 1]:16-21
85. 3 receptor antagonists: differences and similarities. Eur J Cancer 33:1364-1370
86. Ruff P, Paska W, Goedhals L. et al (1994) Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology 51:113-118
87. Schmoll H-J (1992) Quality of life measurements in anti-emetic trials: a discussion of Professor Selby's paper. Br J Cancer 19:S24-25
88. 3 receptor antagonists, a new approach in emesis: a review of ondansetron, granisetron and tropisetron. Anticancer Drugs 2:343-355
89. Seynaeve C, Schulier J, Brunner KW, et al (1992) Comparison of the anti-emetic efficacy of different doses of ondansetron given as either a continuous infusion or a single intravenous dose in acute cisplatin-induced emesis: a multicentre, double-blind, randomised, parallel group study. Br J Cancer 66:192-197
90. Sledge GW, Einhorn LH, Nagy C, et al (1992) Phase III double blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin based chemotherapy. Cancer 70:2524-2528
91. Smith IE (1990) A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. Eur J Cancer 26 [Suppl 1]:519-523
92. Smith IE, on behalf of the Granisetron Study Group (1994) Anti-emetic treatment with granisetron in patients receiving moderately emetogenic chemotherapy. Eur J Clin Res 5:193-202
93. Smith TJ (1996) Reducing the cost of supportive care. II. Anti-emetics. Clin Oncol Alert 11:62-64
94. 3 antagonists ICS 205-930 with a metoclopramide-containing antiemetic cocktail in patients receiving cisplatin chemotherapy. Ann Oncol 1 [Suppl 9]:17
95. Soukop M on the behalf of the Granisetron Study Group (1990) A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. Eur J Cancer 26 [Suppl 1]:15-19
96. Soukop M, McQuade B, Hunter E, et al (1992) Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology 49:295-304
97. Stewart A, McQuade B, Cronje JDE, et al (1995) Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Oncology 52:202-210
98. Stewart DJ (1990) Cancer therapy, vomiting and antiemetics. Can J Physiol Pharmacol 68:304-313
99. Stewart L, Crawford SM (1996) A double blind randomised trial of granisetron + dexamethasone (dex) v ondansetron + dex in the treatment of cisplatin associated nausea and vomiting (abstract 102). Br J Cancer 73 [Suppl 26]:51
100. Talley NJ (1992) 5-Hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications (review). Aliment Pharmacol Ther 6:273-289
101. Tavorath R, Hesketh PJ (1996) Drug treatment of chemotherapy-induced delayed emesis. Drugs 52:639-648
102. Thwaites R, Parasuraman TV, Paska W (1996) Re: 'Cost effectiveness of 5-hydroxytryptamine3 receptor antagonists: a retrospective comparison of ondansetron and granisetron'. Anticancer Drugs 7:127-129
103. Tonato M, Roila F, Del Favero A (1994) Are there differences among the serotonin antagonists? Support Care Cancer 2:293-296
104. Tsavaris NB, Tsaroucha-Noutsou E, Karvounis N, et al (1995) Comparison of different schedules of ondansetron (GR 38032F) administration during cisplatin-based chemotherapy: a randomized trial. Chemotherapy 41:70-76
105. Van Belle SJP, Stamatakis L, Bleiberg H, et al (1995) Dose-finding study of tropisetron in cisplatin-induced emesis. J Clin Oncol 13:1242-1248
106. Warr D (1997) Standard treatment of chemotherapy-induced emesis. Support Care Cancer 5:12-16
107. Whitehead VM (1975) Cancer treatment needs better antiemetics. N Engl J Med 293:199-200